- Home
- JAGX
JAGX
Jaguar Health Inc.
as 04-02-2025 4:00pm EST
Jaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its product Mytesi is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders. It has two reportable segments namely human health and animal health. The company generates the majority of its revenue from the Human Health segment.
| Founded: | 2013 | Country: | United States |
| Employees: | N/A | City: | SAN FRANCISCO |
| Market Cap: | 3.1M | IPO Year: | N/A |
| Target Price: | N/A | AVG Volume (30 days): | 39.3K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -130.69 | EPS Growth: | N/A |
| 52 Week Low/High: | $4.40 - $540.00 | Next Earning Date: | 03-31-2025 |
| Revenue: | $11,689,000 | Revenue Growth: | 19.75% |
| Revenue Growth (this year): | 18.18% | Revenue Growth (next year): | 40.06% |
Latest Jaguar Health Inc. News
JAGX Breaking Stock News: Dive into JAGX Ticker-Specific Updates for Smart Investing
ACCESS Newswire
a day ago
Jaguar Health Announces Closing of Bridge Financing Priced At-The-Market Under Nasdaq Rules
ACCESS Newswire
3 days ago
Jaguar Health Reports 2024 Financials: 2024 Net Revenue Up Approximately 20% Over 2023
ACCESS Newswire
6 days ago
83.33% of Veterinary Oncologists Highlight Importance of Jaguar Health's FDA Conditionally Approved Canalevia-CA1 as a Non-Antibiotic Treatment for Chemotherapy-Induced Diarrhea (CID) in Dog's in New Survey
ACCESS Newswire
7 days ago
Jaguar Health Meeting with FDA Regarding Results of Phase 3 OnTarget Study
MT Newswires
7 days ago
Sector Update: Health Care
ACCESS Newswire
8 days ago
Jaguar Health Presenting March 27 at Emerging Growth Conference and Holding Investor Webcast March 31 Regarding Q4 2024 Financials & Near-Term Catalysts
MT Newswires
8 days ago
Jaguar Health Executives Invest in $3.5 Million Bridge Financing; Shares Fall
ACCESS Newswire
8 days ago
Jaguar Health CEO, Board Members, Other C-Suite Members, and Institutional and Accredited Investors Invest in $3.448 Million Bridge Financing Priced At-The-Market Under Nasdaq Rules
Compare JAGX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "JAGX Jaguar Health Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.